BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32680878)

  • 1. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis.
    Jianguo L; Zhixuan Z; Rong L; Xiaodong S
    Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC
    Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
    Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
    Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
    Keenan C; Nichols KE; Albeituni S
    Front Immunol; 2021; 12():614704. PubMed ID: 33664745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
    Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
    Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale.
    Trantham T; Auten J; Muluneh B; Van Deventer H
    J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
    Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T
    Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review.
    Wang S; Wu J; Jing X; Zhang Y; Tang H; Wu J
    Hematology; 2019 Dec; 24(1):751-756. PubMed ID: 33138732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
    Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE
    Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH.
    Wang H; Gu J; Liang X; Mao X; Wang Z; Huang W
    Semin Hematol; 2020 Jan; 57(1):26-30. PubMed ID: 32690141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alleviating the storm: ruxolitinib in HLH.
    La Rosée P
    Blood; 2016 Mar; 127(13):1626-7. PubMed ID: 27034417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report.
    Sin JH; Zangardi ML
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report.
    Yan WL; Yang SL; Zhao FY; Xu XJ
    J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.
    Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B
    Front Immunol; 2022; 13():1012643. PubMed ID: 36263041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
    Soy M; Atagündüz P; Atagündüz I; Sucak GT
    Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis.
    Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R
    Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
    Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis.
    Chi Y; Liu R; Zhou ZX; Shi XD; Ding YC; Li JG
    Pediatr Rheumatol Online J; 2021 Apr; 19(1):49. PubMed ID: 33794928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
    Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
    Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome.
    Zhou L; Liu Y; Wen Z; Yang S; Li M; Zhu Q; Qiu S; Gao Y; Wang H; Yuan Y; Zhang H; Chen C; Zeng W; Guan Z; Pan X
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3063-3074. PubMed ID: 32617699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.